KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Safety and Immunogenicity of sIPV in Healthy Infants Aged 2 Months Following Sequential Immunization Program Combination with bOPV: A Phase 3, Randomized, Blinded, Parallel Positive-Controlled Clinical Trial.

Yafei Liu, Xiaodong Liu, Li Zhang, Xianyun Chang, Ping Xiong, Yanxin Guan, Yixin Li, Weiling Zhang, Lili Xuan, Yan Li, Zhifang Ying, Qing Xu

Vaccines (Basel) 13(11) 1094

PMID41295467
PMCIDPMC12656725
DOI10.3390/vaccines13111094
发表日期2025-11-26
摘要

摘要

Objectives: This phase 3 clinical trial aimed to evaluate the safety and immunogenicity of the Sabin inactivated poliovirus vaccine (sIPV) manufactured by Biominhai in healthy infants following a sequential immunization regimen. Methods: A total of 300 healthy infants aged 2 months were randomly divided into the test group (sIPV-sIPV-bOPV) and the control group (wIPV-wIPV-bOPV) according to the ratio of 1:1. Both groups were inoculated under "2IPV + 1bOPV" schedule. Safety was assessed alongside poliovirus antibody levels before and after vaccination. Results: The overall incidence of adverse reactions (AEs) in the test and control groups was 44% and 39%, respectively. AEs in both groups primarily occurred following the first dose, with approximately 30% classified as grade 1 in severity. No significant differences were observed between groups regarding the incidence, severity, and symptoms of AEs. Additionally, no vaccine-related serious adverse events (SAEs) were reported. At 30 days after the last dose, the seroconversion rates of neutralizing antibodies against poliovirus types I and III reached 100% in both groups, while type II rates at 99% for the test group and 95% for the control. Notably, the seroconversion rates for all types in the test group were non-inferior to those in the control group. The geometric mean titers (GMTs) of neutralizing antibodies against poliovirus for type I (8622.64 vs. 2687.65), type II (207.73 vs. 54.06), and type III (2121.74 vs. 1699.12) were significantly higher in the test group (p < 0.0001 for type I and II; p = 0.04 for type III). Conclusions: The study concluded that the trial vaccine sIPV following sequential immunization program demonstrates good safety and immunogenicity, showing non-inferiority to the control vaccine.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。